AP2369A - Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. - Google Patents

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Info

Publication number
AP2369A
AP2369A AP2008004506A AP2008004506A AP2369A AP 2369 A AP2369 A AP 2369A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2369 A AP2369 A AP 2369A
Authority
AP
ARIPO
Prior art keywords
pyrrolopyrazoles
carbonylamino
kinase inhibitors
potent kinase
potent
Prior art date
Application number
AP2008004506A
Other languages
English (en)
Other versions
AP2008004506A0 (en
Inventor
Liming Dong
Chuangxing Guo
Yufeng Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2008004506A0 publication Critical patent/AP2008004506A0/xx
Application granted granted Critical
Publication of AP2369A publication Critical patent/AP2369A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2008004506A 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. AP2369A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (2)

Publication Number Publication Date
AP2008004506A0 AP2008004506A0 (en) 2008-06-30
AP2369A true AP2369A (en) 2012-02-29

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004506A AP2369A (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Country Status (26)

Country Link
US (1) US7884117B2 (xx)
EP (1) EP1979356B1 (xx)
JP (1) JP4635089B2 (xx)
KR (1) KR101029167B1 (xx)
AP (1) AP2369A (xx)
AU (1) AU2006327866B2 (xx)
BR (1) BRPI0620354A2 (xx)
CA (1) CA2634381C (xx)
CR (1) CR10094A (xx)
CU (1) CU23751B7 (xx)
DK (1) DK1979356T3 (xx)
EA (1) EA015513B1 (xx)
EC (1) ECSP088558A (xx)
ES (1) ES2435405T3 (xx)
GE (1) GEP20104974B (xx)
HR (1) HRP20130976T1 (xx)
IL (1) IL191776A (xx)
MA (1) MA30076B1 (xx)
ME (1) MEP0808A (xx)
MY (1) MY151455A (xx)
NO (1) NO20082482L (xx)
NZ (1) NZ568692A (xx)
PL (1) PL1979356T3 (xx)
PT (1) PT1979356E (xx)
RS (2) RS20080281A (xx)
WO (1) WO2007072153A2 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP5868324B2 (ja) * 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
KR20130121122A (ko) 2010-11-17 2013-11-05 에프. 호프만-라 로슈 아게 종양의 치료 방법
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
KR20140135198A (ko) 2012-03-16 2014-11-25 에프. 호프만-라 로슈 아게 Pak1 억제제로 흑색종을 치료하는 방법
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. キラル制御
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JP6690543B2 (ja) 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
AU2015371251B2 (en) * 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2989519C (en) 2015-06-15 2023-09-26 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US12304913B2 (en) 2018-11-14 2025-05-20 Ube Industries, Ltd. Dihydropyrrolopyrazole derivative
JP7660063B2 (ja) * 2018-12-28 2025-04-10 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼ7のインヒビターおよびそれらの使用
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
AU2005323797B2 (en) * 2005-01-10 2009-07-09 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
AU2006327866B2 (en) 2012-06-14
ES2435405T3 (es) 2013-12-19
HK1128290A1 (en) 2009-10-23
CU23751B7 (es) 2012-01-31
WO2007072153A2 (en) 2007-06-28
EP1979356B1 (en) 2013-09-18
JP4635089B2 (ja) 2011-02-16
GEP20104974B (en) 2010-04-26
AU2006327866A1 (en) 2007-06-28
CA2634381C (en) 2011-03-08
IL191776A (en) 2013-03-24
JP2009520805A (ja) 2009-05-28
MY151455A (en) 2014-05-30
ME00006B (me) 2010-02-10
IL191776A0 (en) 2008-12-29
ECSP088558A (es) 2008-07-30
RS20080281A (sr) 2009-09-08
MEP0808A (xx) 2010-02-10
NO20082482L (no) 2008-07-02
KR20080080567A (ko) 2008-09-04
RS53029B (sr) 2014-04-30
US7884117B2 (en) 2011-02-08
AP2008004506A0 (en) 2008-06-30
WO2007072153A3 (en) 2007-10-25
PT1979356E (pt) 2013-11-21
CA2634381A1 (en) 2007-06-28
MA30076B1 (fr) 2008-12-01
EA015513B1 (ru) 2011-08-30
WO2007072153A8 (en) 2008-08-14
CU20080115A7 (es) 2010-08-30
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
EA200801291A1 (ru) 2008-12-30
KR101029167B1 (ko) 2011-04-12
BRPI0620354A2 (pt) 2011-11-08
US20090318440A1 (en) 2009-12-24
DK1979356T3 (da) 2013-11-18
NZ568692A (en) 2011-07-29
HRP20130976T1 (hr) 2013-11-22
PL1979356T3 (pl) 2014-01-31

Similar Documents

Publication Publication Date Title
AP2369A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
IL184275A0 (en) Pyrrolopyrazoles, potent kinase inhibitors
EG25264A (en) Biphenyl-n-(4-pyridyl) methylsulfonamides.
AP2402A (en) Amine derivatives.
IL190078A0 (en) Kinase inhibitors
EG25271A (en) Fungicidal combinations.
GB2424882B (en) Selective kinase inhibitors
SI2270008T1 (sl) 8-heteroaril-3-alkil-1,3-dihidro-imidazo(4,5-c)kinolin-2-oni kot inhibitorji PI-3 kinaz
IL192033A0 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AP2006003659A0 (en) Azabenzofuran substituted thioureas, inhibitors ofviral replication
AP2281A (en) Novel compounds.
PL1943243T3 (pl) Inhibitory kinazy
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
AP2337A (en) Motilide compounds.
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
ZA200804667B (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
NL1031384A1 (nl) Gesubstitueerde aryl-1,4-pyrazinederivaten.
GB0505823D0 (en) Boardmate, boardmate adjustable
GB0504761D0 (en) Alfatie, Coliawel, Omaatie
ITRM20050033U1 (it) Semicabina per fumatori.
ITTO20050072U1 (it) Armadio-espositore, particolarmente per tabaccherie
ZA200803287B (en) Kinase inhibitors
IL189985A0 (en) Kinase inhibitors
CY2449B1 (en) Multiple srengthened carton.
PL378279A1 (pl) Układ do osuszania gazów zwłaszcza dla komór klimatycznych